Skip to main content

Bristol-Myers Squibb Company

Founders

Who Founded Bristol-Myers Squibb?

Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers · Founded 1887 · HQ today: Princeton, New Jersey

Who founded Bristol-Myers Squibb?

Bristol-Myers Squibb was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers in 1887. It is now led by Chris Boerner.

Founders
Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers
Founded
1887
Headquarters
Princeton, New Jersey
Number of founders
3
Current CEO
Chris Boerner (since 2023)
Where was Bristol-Myers Squibb founded?
Bristol-Myers Squibb was founded in New York City, New York in 1887.
When was Bristol-Myers Squibb founded?
Bristol-Myers Squibb was founded in 1887.
Who started Bristol-Myers Squibb?
Bristol-Myers Squibb was founded by Edward Robinson Squibb, William McLaren Bristol and John Ripley Myers.
How old is Bristol-Myers Squibb?
Bristol-Myers Squibb is 139 years old as of 2026.

Founding Story

Two separate 19th-century businesses became BMS. In 1858 Navy surgeon Edward Robinson Squibb opened a laboratory in Brooklyn to make pure ether and other medicines; it burned down that Christmas Eve, and local doctors put up $2,100 to rebuild it. Squibb went on to supply the Union Army during the Civil War. In 1887 Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company in Clinton, New York, which became Bristol-Myers and found national success with Sal Hepatica laxative salts and Ipana toothpaste. The two companies merged in 1989.

Edward Robinson Squibb

Co-founder 1858

Background

Edward Robinson Squibb (1819-1900) was a physician and U.S. Navy surgeon who became frustrated by the impure, inconsistent medicines of the 1850s and developed a steam-distillation method for making pure ether.

Role at Bristol-Myers Squibb Company

Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines. The laboratory burned down on Christmas Eve that year; a group of doctors and surgeons put up $2,100 so he could reopen in 1859. He published his ether method rather than patenting it, supplied medicines to the Union Army during the Civil War, and pushed for stricter purity standards, self-publishing Squibb's Ephemeris of Materia Medica when the American Medical Association would not adopt them. His sons Charles and Edward took over as his health declined, and the firm became E.R. Squibb & Sons in 1895. They sold it in 1905, and Squibb merged with Bristol-Myers in 1989. Edward Robinson Squibb was born in 1819.

Background

William McLaren Bristol was a Hamilton College graduate who went into business with his classmate John Ripley Myers rather than into science.

Role at Bristol-Myers Squibb Company

In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000. The business was renamed Bristol, Myers and Company in May 1898, and after Myers died in 1899 Bristol renamed it the Bristol-Myers Corporation. Its first nationally recognized product was Sal Hepatica, a laxative mineral salt sold from the 1890s, followed by Ipana toothpaste in 1901. Under the Bristol family the company grew into a consumer and pharmaceutical group that later added Clairol and Drackett and entered antibiotics after World War II, before merging with Squibb in 1989.

William McLaren Bristol was born in 1860.

John Ripley Myers

Co-founder 1887

Background

John Ripley Myers was a Hamilton College graduate and the co-investor alongside William McLaren Bristol in the 1887 purchase that started Bristol-Myers.

Role at Bristol-Myers Squibb Company

Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898. Myers died in 1899, before the company's first national brands took off, but his name stayed on the business through the 1989 merger that created Bristol-Myers Squibb.

John Ripley Myers was born in 1864.

Myers was born on October 8, 1864 and died on December 22, 1899.

Bristol-Myers Squibb Company: CEO & Leadership History

Full timeline →

Chris Boerner

Board Chair and Chief Executive Officer

2023 – Present

Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer. He closed the Karuna and RayzeBio deals, oversaw the September 2024 approval of Cobenfy, signed the June 2025 BioNTech partnership and the October 2025 Orbital Therapeutics purchase, and expanded cost cuts to prepare for the 2028 loss of U.S. exclusivity on Eliquis and Opdivo. In July 2026 he raised 2026 revenue guidance to $49.0 to $50.0 billion.

Giovanni Caforio

Chief Executive Officer

2015 – 2023

Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023. He handed the CEO role to Chris Boerner in November 2023, stepped down as board chair on April 1, 2024 and retired after 23 years at the company.

Lamberto Andreotti

Chief Executive Officer

2010 – 2015

Andreotti, previously president and chief operating officer, became CEO on May 4, 2010. His tenure saw the approvals of Yervoy (2011), Eliquis (2012) and Opdivo (2014), the 2012 purchases of Inhibitex and Amylin, and the 2014 sale of the diabetes business to AstraZeneca. He retired as CEO in 2015 and was succeeded by Giovanni Caforio.

James M. Cornelius

Chief Executive Officer

2006 – 2010

Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010. He led the 'String of Pearls' strategy of biotech deals and alliances, bought Medarex in 2009, sold ConvaTec and split off Mead Johnson Nutrition, turning BMS into a specialty biopharmaceutical company.

Peter R. Dolan

Chief Executive Officer

2001 – 2006

Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices. He was removed on September 12, 2006 at the urging of the federal monitor after a patent settlement with Apotex over Plavix.

Charles A. Heimbold Jr.

Chief Executive Officer

1994 – 2001

Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.

Compare Bristol-Myers Squibb Company Leadership With Competitors

Keep researching Bristol-Myers Squibb

Who Founded Bristol-Myers Squibb? FAQ

What are the 19th-century founding origins of Bristol-Myers Squibb?

Bristol-Myers Squibb traces its heritage to two foundational American pharmaceutical companies: E.R. Squibb & Sons (founded in Brooklyn, New York, in 1858 by Dr. Edward Robinson Squibb) and Bristol, Myers and Company (founded in Clinton, New York, in 1887 by William McLaren Bristol and John Ripley Myers).

Who was Dr. Edward Robinson Squibb and what was his historical contribution to medicine?

Edward Robinson Squibb (1819-1900) was a U.S. Navy surgeon who developed a steam-distillation method for pure ether, published it rather than patenting it, opened his Brooklyn laboratory in 1858 and argued for stricter purity standards, self-publishing Squibb's Ephemeris of Materia Medica.

How did William McLaren Bristol and John Ripley Myers found Bristol-Myers in 1887?

In 1887, Hamilton College graduates William McLaren Bristol and John Ripley Myers invested $5,000 to purchase the failing Clinton Pharmaceutical Company in Clinton, New York, successfully turning it profitable and rebranding it as Bristol, Myers and Company in 1898.

What was Sal Hepatica and how did it establish Bristol-Myers' early commercial success?

Sal Hepatica, a laxative mineral salt, became Bristol-Myers' first nationally recognized product in the 1890s. Ipana toothpaste followed in 1901, and the consumer business later grew to include Clairol and Drackett.

How did Squibb mass-produce penicillin during World War II?

Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey, in 1944. Bristol-Myers bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to produce penicillin for Allied forces.

When did Bristol-Myers and Squibb merge?

In 1989, creating Bristol-Myers Squibb Company. The company now does business as Bristol Myers Squibb, without the hyphen, and is headquartered in Princeton, New Jersey.

What historic cardiovascular and oncology breakthroughs did the legacy companies discover?

Squibb developed Capoten (captopril), the first ACE inhibitor for high blood pressure, approved in 1981. Bristol-Myers brought the chemotherapy Platinol (cisplatin) to market in 1978 and commercialized Taxol (paclitaxel), discovered through U.S. National Cancer Institute research, in 1992.

What enduring medical ethics legacy did the founders leave behind?

Squibb's long-running motto held that the priceless ingredient of every product is the honor and integrity of its maker, a line that reflected Edward Squibb's focus on purity and quality control.

Who founded Bristol-Myers Squibb?

The original companies were founded by William McLaren Bristol and John Ripley Myers (Bristol-Myers in 1887) and Dr. Edward Robinson Squibb (Squibb in 1858).

Related Founder Profiles

Compare founding stories, origins, and entrepreneurial journeys

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.